BRPI0410055A - antagonistas de receptor de glutamato como neuroprotetores - Google Patents

antagonistas de receptor de glutamato como neuroprotetores

Info

Publication number
BRPI0410055A
BRPI0410055A BRPI0410055-7A BRPI0410055A BRPI0410055A BR PI0410055 A BRPI0410055 A BR PI0410055A BR PI0410055 A BRPI0410055 A BR PI0410055A BR PI0410055 A BRPI0410055 A BR PI0410055A
Authority
BR
Brazil
Prior art keywords
glutamate receptor
neuroprotectors
receptor antagonists
glutamate
relates
Prior art date
Application number
BRPI0410055-7A
Other languages
English (en)
Inventor
Wolfgang S Hngen
Original Assignee
Paion Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paion Deutschland Gmbh filed Critical Paion Deutschland Gmbh
Publication of BRPI0410055A publication Critical patent/BRPI0410055A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49Urokinase; Tissue plasminogen activator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"ANTAGONISTAS DE RECEPTOR DE GLUTAMATO COMO NEUROPROTETORES". A invenção refere-se ao uso de um inibidor de ativação mediada por t-PA do receptor de glutamato, preferivelmente do tipo NMDA, como neuroprotetor.
BRPI0410055-7A 2003-05-05 2004-05-05 antagonistas de receptor de glutamato como neuroprotetores BRPI0410055A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10337098 2003-05-05
DE10320336 2003-05-06
DE10352333 2003-11-06
PCT/EP2004/004776 WO2004098635A1 (de) 2003-05-05 2004-05-05 Glutamat-rezeptor-antagonisten als neuroprotektiva

Publications (1)

Publication Number Publication Date
BRPI0410055A true BRPI0410055A (pt) 2006-04-25

Family

ID=33436868

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410055-7A BRPI0410055A (pt) 2003-05-05 2004-05-05 antagonistas de receptor de glutamato como neuroprotetores

Country Status (12)

Country Link
US (1) US20080213244A1 (pt)
EP (1) EP1622640A1 (pt)
JP (1) JP2006525277A (pt)
KR (1) KR20060015721A (pt)
AU (1) AU2004237407A1 (pt)
BR (1) BRPI0410055A (pt)
CA (1) CA2524342A1 (pt)
EA (1) EA200501753A1 (pt)
HR (1) HRP20050898A2 (pt)
MX (1) MXPA05011762A (pt)
NO (1) NO20055725L (pt)
WO (1) WO2004098635A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
CA2612262A1 (en) * 2005-06-24 2006-12-28 Wilex Ag Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases
AR068914A1 (es) * 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786187A (en) * 1995-09-21 1998-07-28 The Research Foundation Of State University Of New York Method for reducing neuronal degeneration associated with seizure
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall

Also Published As

Publication number Publication date
KR20060015721A (ko) 2006-02-20
MXPA05011762A (es) 2006-03-30
AU2004237407A1 (en) 2004-11-18
HRP20050898A2 (en) 2007-03-31
US20080213244A1 (en) 2008-09-04
WO2004098635A1 (de) 2004-11-18
JP2006525277A (ja) 2006-11-09
CA2524342A1 (en) 2004-11-18
NO20055725D0 (no) 2005-12-02
EA200501753A1 (ru) 2006-04-28
NO20055725L (no) 2005-12-02
EP1622640A1 (de) 2006-02-08

Similar Documents

Publication Publication Date Title
DK1337518T3 (da) Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
BR0209242A (pt) Aminopolidiorganossiloxanos amido-funcionais
TNSN07196A1 (en) Potentiators of glutamate receptors
GB0115862D0 (en) Compounds
CR7728A (es) Nuevas quinazolinas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
TW200612945A (en) Aerosol suspension formulations containing TG 227 ea as propellant
SMP200600024B (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina
UA87862C2 (en) 4-benzylidene-piperidin derivatives
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
DK1444215T3 (da) 1,2,4-Thiadiazoliumderivater som melanocortinreceptormodulatorer
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
EP1962838A4 (en) Farnesoid X RECEPTOR AGONISTS
CY1110828T1 (el) Τροποποιημενοι πυριμιδινικοι ρυθμιστες του γλυκοκορτικοειδους υποδοχεα
TW200800967A (en) Benzimidazole thiophene compounds
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
BRPI0112375B8 (pt) aplidinas como derivados antitumorais
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
TW200517103A (en) Peptides and compounds that bind to a receptor
HK1077827A1 (en) Diazabicyclononane and-decane derivatives their use as opioid receptor ligands
MX2008000874A (es) Metodos y composiciones para anticoncepcion de emergencia utilizando antagonistas del receptor de endotelina.
BRPI0410055A (pt) antagonistas de receptor de glutamato como neuroprotetores
GB0401634D0 (en) A surfactant
MXPA05012279A (es) Derivados de bencil sulfonamida.
AU2003266093A1 (en) Cyclooct-(en-)yl derivatives for use as fragrances
ATE275551T1 (de) Halogenpyrimidine

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.